Log in for full access to this activity, if you are registered.

Registration Options

Activity Dates: 06/01/2018 - 04/23/2021

Target Audience

This course is designed for pharmacists and/or other healthcare professionals involved in the medication management of individuals living with psychiatric, neurologic and/or substance use disorders.

Session Summary

Over 5 million people in the United States are living with chronic hepatitis C viral (HCV) infection. Psychiatric illnesses are considered a barrier to achieving sustained virological response (SVR) in patients with HCV but early detection and treatment of depression can improve antiviral adherence. Depressive disorder is a commonly existing comorbidity of HCV, with an estimated prevalence of 14%. Insomnia is associated with specific direct-acting antivirals (DAAs), requiring treatment for some during the 12-24 weeks of treatment and post-treatment surveillance. Psychiatric pharmacists can help improve adherence with antiviral medications by concomitantly managing psychiatric symptoms and monitoring symptom response. In addition to performing baseline psychiatric evaluations and managing interferon-induced psychiatric symptoms, psychiatric pharmacists should provide patient education on HCV and the antiviral medications, and manage drug-drug interactions prior to initiating DAAs. This session will provide training enabling psychiatric pharmacists to perform the basic duties of a clinical hepatic pharmacist, while influencing psychiatric care for patients infected with HCV who require antiviral treatment but develop psychiatric adverse drug reactions.

Course Requirements

You will proceed through the following steps to satisfactorily complete this course:

  • Review the full content of the activity and reflect upon its teachings.
  • Complete the post-test at the end of the activity no later than the closing activity date. (login first)
  • Complete the evaluation at the end of the activity. (login first)
  • If necessary, complete the post-test retest no later than the closing activity date. (login first)
  • Receive a passing grade (70%).
  • Provide the necessary details in your profile to ensure correct reporting by CPNP to CPE Monitor. (login first)

Participants in this course must complete an examination and achieve a score of 70% or greater. Successful completion of the course also requires the completion of a course evaluation. Upon successful completion, ACPE credit is reported immediately to CPE Monitor although transcripts can be retrieved by participants online at http://cpnp.org/mycpnp/transcript/acpe.

Faculty Information and Disclosures

Susie H. Park, PharmD, BCPP, FCSHP

View biographical information and disclosures

Learning Objectives

  1. Devise a treatment and monitoring plan for a patient infected with chronic hepatitis C virus (HCV), from pre-treatment evaluation to post-treatment surveillance.
  2. Evaluate the psychiatric pharmacist’s role in providing patient education, managing antiviral-induced adverse drug reactions, evaluating drug interactions, and encouraging medication adherence for HCV-infected patients.
  3. Recommend pharmacologic and non-pharmacologic treatment in an HCV-infected patient with depression or insomnia.

Continuing Education Credit and Disclosures

Activity Dates: 06/01/2018 - 04/23/2021
ACPE Contact Hours: 1.0
ACPE Number: 0284-0000-18-032-H01-P (Application)
Nursing Credit Reminder: Note that ACPE credit is accepted for certification renewal.

ACPEThe College of Psychiatric and Neurologic Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This course provides 1.0 contact hour of application-based continuing education credit from CPNP approved programming.